

Leslie Citrome

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5314670/publications.pdf>

Version: 2024-02-01

495
papers

15,723
citations

18482

62
h-index

28297

105
g-index

518
all docs

518
docs citations

518
times ranked

10118
citing authors

#	ARTICLE	IF	CITATIONS
1	Perceived Burdens and Educational Needs of Caregivers of People with Schizophrenia: Results of a National Survey Study. Patient Preference and Adherence, 2022, Volume 16, 159-168.	1.8	5
2	Management of Schizophrenia with Long-Acting Injectable Antipsychotic Medications: An Assessment of the Educational Needs of Clinicians. Neuropsychiatric Disease and Treatment, 2022, Volume 18, 111-123.	2.2	8
3	Effect of Sublingual Dexmedetomidine vs Placebo on Acute Agitation Associated With Bipolar Disorder. JAMA - Journal of the American Medical Association, 2022, 327, 727.	7.4	36
4	How Would You Like to Take Your Medicine 2 Times a Year? Paliperidone Palmitate Every 6 Months for the Maintenance Treatment of Schizophrenia. Clinical Therapeutics, 2022, 44, 476-479.	2.5	2
5	Olanzapine-samidorphan combination tablets for the treatment of schizophrenia and bipolar I disorder - what is it, and will it be used?. Expert Review of Neurotherapeutics, 2022, , .	2.8	3
6	An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels. Pharmacopsychiatry, 2022, 55, 73-86.	3.3	107
7	Hallucinations and delusions associated with Parkinson's disease psychosis: safety of current treatments and future directions. Expert Opinion on Drug Safety, 2022, 21, 873-879.	2.4	7
8	Effect of the HP-3070 Transdermal System (Secuado) on Symptoms of Hostility in Adults with Schizophrenia. CNS Spectrums, 2022, 27, 241-241.	1.2	0
9	Excess healthcare resource utilization and healthcare costs among privately and publicly insured patients with major depressive disorder and acute suicidal ideation or behavior in the United States. Journal of Affective Disorders, 2022, 311, 303-310.	4.1	4
10	Binge Eating Disorder: A Psychiatrist's Commentary on Clinical Considerations. Clinical Therapeutics, 2021, 43, 7-16.	2.5	1
11	Does antipsychotic combination therapy reduce the risk of hospitalization in schizophrenia?. Expert Opinion on Pharmacotherapy, 2021, 22, 635-646.	1.8	6
12	Real-World Medication Treatment Patterns for Long-Term Care Residents with Dementia-Related Psychosis. Gerontology and Geriatric Medicine, 2021, 7, 233372142110165.	1.5	2
13	Long-acting injectable antipsychotics: what, when, and how. CNS Spectrums, 2021, 26, 118-129.	1.2	20
14	Pharmacokinetic Profile of the Asenapine Transdermal System (HP-3070). Journal of Clinical Psychopharmacology, 2021, 41, 286-294.	1.4	11
15	Using Item 8 of the Abnormal Involuntary Movement Scale (AIMS) to Assess Improvement in Patients with Tardive Dyskinesia. CNS Spectrums, 2021, 26, 152-152.	1.2	0
16	A Combination of Olanzapine and Samidorphan in Adults with Schizophrenia and Bipolar I Disorder: Overview of Clinical Data. CNS Spectrums, 2021, 26, 170-170.	1.2	1
17	Assessing the Benefit-Risk Ratio of Approved Treatments for Bipolar Depression Using Likelihood to be Helped or Harmed (LHH) Analyses. CNS Spectrums, 2021, 26, 146-146.	1.2	0
18	Assessment of the Impact of Tardive Dyskinesia in Clinical Practice: Consensus Panel Recommendations. Neuropsychiatric Disease and Treatment, 2021, Volume 17, 1589-1597.	2.2	11

#	ARTICLE	IF	CITATIONS
19	Cariprazine and akathisia, restlessness, and extrapyramidal symptoms in patients with bipolar depression. <i>Journal of Affective Disorders</i> , 2021, 288, 191-198.	4.1	7
20	Lemborexant for the Treatment of Insomnia. <i>Journal of Clinical Psychiatry</i> , 2021, 82, .	2.2	11
21	Benefitâ€“Risk Assessment of Galcanezumab Versus Placebo for the Treatment of Episodic and Chronic Migraine Using the Metrics of Number Needed to Treat and Number Needed to Harm. <i>Advances in Therapy</i> , 2021, 38, 4442-4460.	2.9	2
22	Measurement-based Diagnosis and Treatment for Tardive Dyskinesia. <i>Journal of Clinical Psychiatry</i> , 2021, 82, .	2.2	2
23	Advances in the Treatment of Chronic Insomnia: A Narrative Review of New Nonpharmacologic and Pharmacologic Therapies. <i>Neuropsychiatric Disease and Treatment</i> , 2021, Volume 17, 2549-2566.	2.2	22
24	Prevalence of Pre-existing Conditions Relevant for Adverse Events and Potential Drugâ€“Drug Interactions Associated with Augmentation Therapies Among Patients with Treatment-Resistant Depression. <i>Advances in Therapy</i> , 2021, 38, 4900-4916.	2.9	5
25	An Evidence-Based Review of OLZ/SAM for Treatment of Adults with Schizophrenia or Bipolar I Disorder. <i>Neuropsychiatric Disease and Treatment</i> , 2021, Volume 17, 2885-2904.	2.2	9
26	Long-acting injectable antipsychotics: what, when, and how â€“ CORRIGENDUM. <i>CNS Spectrums</i> , 2021, , 1-1.	1.2	4
27	Asenapine: an atypical antipsychotic with atypical formulations. <i>Therapeutic Advances in Psychopharmacology</i> , 2021, 11, 204512532110352.	2.7	11
28	Specific Anti-hostility Effects of Atypical Antipsychotics in Persons with Schizophrenia: From Clozapine to Cariprazine. <i>Harvard Review of Psychiatry</i> , 2021, 29, 20-34.	2.1	11
29	Eating Disorders Update 2021: What We Know, What We Don't Know, and Next Steps. <i>Clinical Therapeutics</i> , 2021, 43, 4-6.	2.5	0
30	Tardive Dyskinesia in Older Persons Taking Antipsychotics. <i>Neuropsychiatric Disease and Treatment</i> , 2021, Volume 17, 3127-3134.	2.2	9
31	Diagnostic and Treatment Fundamentals for Tardive Dyskinesia. <i>Journal of Clinical Psychiatry</i> , 2021, 82, .	2.2	1
32	Agitation in schizophrenia: origins and evidence-based treatment. <i>Current Opinion in Psychiatry</i> , 2021, 34, 216-221.	6.3	3
33	Health care resource use, short-term disability days, and costs associated with states of persistence on antidepressant lines of therapy. <i>Journal of Medical Economics</i> , 2021, 24, 1299-1308.	2.1	0
34	New discoveries for an old drug: a review of recent olanzapine research. <i>Postgraduate Medicine</i> , 2020, 132, 80-90.	2.0	38
35	Food and Drug Administrationâ€“Approved Treatments for Acute Bipolar Depression. <i>Journal of Clinical Psychopharmacology</i> , 2020, 40, 334-338.	1.4	6
36	Intravenous brexanolone for postpartum depression: what it is, how well does it work, and will it be used?. <i>Therapeutic Advances in Psychopharmacology</i> , 2020, 10, 204512532096865.	2.7	15

#	ARTICLE	IF	CITATIONS
37	Consider Clinical Therapeutics for Your Next Psychiatry Submission. <i>Clinical Therapeutics</i> , 2020, 42, 732-733.	2.5	0
38	Appraising esketamine nasal spray for the management of treatment-resistant depression in adults: Number needed to treat, number needed to harm, and likelihood to be helped or harmed. <i>Journal of Affective Disorders</i> , 2020, 271, 228-238.	4.1	16
39	The treatment of acute agitation associated with schizophrenia or bipolar disorder: investigational drugs in early stages of their clinical development, and their clinical context and potential place in therapy. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 245-257.	4.1	7
40	145 Incidence and Characteristics of Akathisia and Restlessness During Cariprazine Treatment for Bipolar I Disorder. <i>CNS Spectrums</i> , 2020, 25, 292-292.	1.2	0
41	146 Efficacy and Safety of the Asenapine Transdermal Patch, HP-3070, for Schizophrenia: A Phase 3, Randomized, Placebo-Controlled, Inpatient Study. <i>CNS Spectrums</i> , 2020, 25, 293-293.	1.2	1
42	144 Esketamine Nasal Spray for Management of Treatment-Resistant Depression: Number Needed to Treat, Number Needed to Harm, Likelihood to be Helped/Harmed. <i>CNS Spectrums</i> , 2020, 25, 291-292.	1.2	0
43	168 Effect of Dasotraline on Body Weight in Patients with Binge-Eating Disorder. <i>CNS Spectrums</i> , 2020, 25, 307-307.	1.2	1
44	169 Dasotraline for Treatment of Adults with Binge-Eating Disorder: Effect on Binge-related Obsessions and Compulsions. <i>CNS Spectrums</i> , 2020, 25, 307-308.	1.2	1
45	A Modified Delphi Consensus Study of the Screening, Diagnosis, and Treatment of Tardive Dyskinesia. <i>Journal of Clinical Psychiatry</i> , 2020, 81, .	2.2	13
46	Blood Levels to Optimize Antipsychotic Treatment in Clinical Practice. <i>Journal of Clinical Psychiatry</i> , 2020, 81, .	2.2	86
47	Olanzapine Plus Samidorphan (ALKS 3831) in Schizophrenia and Comorbid Alcohol Use Disorder. <i>Journal of Clinical Psychiatry</i> , 2020, 81, .	2.2	17
48	Efficacy and Safety of HP-3070, an Asenapine Transdermal System, in Patients With Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2020, 82, .	2.2	12
49	Revisiting Tardive Dyskinesia. <i>Journal of Clinical Psychiatry</i> , 2020, 81, .	2.2	10
50	Psychopharmacology of Violent Behavior Among People with Severe Mental Disorders. <i>Comprehensive Approach To Psychiatry</i> , 2020, , 253-268.	1.0	0
51	433 - Burden of Disease Associated with Dementia-related Psychosis and Dementia-related Agitation & Aggression Using a National Long-term Care US Database. <i>International Psychogeriatrics</i> , 2020, 32, 149-150.	1.0	0
52	Our impact factor went from 2.000 to 2.613: So what?. <i>International Journal of Clinical Practice</i> , 2019, 73, e13388.	1.7	1
53	Cariprazine for bipolar depression: What is the number needed to treat, number needed to harm and likelihood to be helped or harmed?. <i>International Journal of Clinical Practice</i> , 2019, 73, e13397.	1.7	14
54	Reflections of a semi-colon; Part 2, chemotherapy. <i>International Journal of Clinical Practice</i> , 2019, 73, e13439.	1.7	1

#	ARTICLE	IF	CITATIONS
55	<p>Assessing effectiveness of aripiprazole lauroxil vs placebo for the treatment of schizophrenia using number needed to treat and number needed to harm</p>. Neuropsychiatric Disease and Treatment, 2019, Volume 15, 2639-2646.	2.2	3
56	Looking out for number one. International Journal of Clinical Practice, 2019, 73, e13398.	1.7	0
57	<p>Examining the safety, efficacy, and patient acceptability of inhaled loxapine for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults</p>. Neuropsychiatric Disease and Treatment, 2019, Volume 15, 2273-2283.	2.2	11
58	<p>A commentary on the efficacy of olanzapine for the treatment of schizophrenia: the past, present, and future</p>. Neuropsychiatric Disease and Treatment, 2019, Volume 15, 2559-2569.	2.2	42
59	Disclosures and Conflicts of Interest: Solving the Riddle, Wrapped in a Mystery, Inside an Enigma. Clinical Therapeutics, 2019, 41, 2643-2655.	2.5	1
60	Brexpiprazole for the maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy. Neuropsychiatric Disease and Treatment, 2019, Volume 15, 247-257.	2.2	173
61	Reflections of a semicolon; Part 1, how my gall bladder saved my life. International Journal of Clinical Practice, 2019, 73, e13355.	1.7	1
62	Adherence: A challenge for all. International Journal of Clinical Practice, 2019, 73, e13379.	1.7	0
63	Binge eating disorder revisited: whatâ€™s new, whatâ€™s different, whatâ€™s next. CNS Spectrums, 2019, 24, 4-13.	1.2	40
64	Testing, testing. 1, 2, 3. Is this mic on?. International Journal of Clinical Practice, 2019, 73, e13344.	1.7	0
65	41 A Modified Delphi Consensus Approach to Clinical Guidelines for Tardive Dyskinesia. CNS Spectrums, 2019, 24, 197-198.	1.2	0
66	Think Bayesian, Think Smarter!. International Journal of Clinical Practice, 2019, 73, e13351.	1.7	1
67	Prevalence, treatment patterns, and stay characteristics associated with hospitalizations for major depressive disorder. Journal of Affective Disorders, 2019, 249, 378-384.	4.1	40
68	Patches. Journal of Clinical Psychiatry, 2019, 80, .	2.2	24
69	C.10.04 Exploring treatment decision-making for patients with schizophrenia. European Neuropsychopharmacology, 2019, 29, S596-S597.	0.7	0
70	Goodbye but not farewell: Passing the baton at the International Journal of Clinical Practice. International Journal of Clinical Practice, 2019, 73, e13459.	1.7	0
71	Effect of Brexpiprazole on Agitation and Hostility in Patients With Schizophrenia. Journal of Clinical Psychopharmacology, 2019, 39, 597-603.	1.4	7
72	Resistance is not futile: treatment-refractory schizophrenia â€™ overview, evaluation and treatment. Expert Opinion on Pharmacotherapy, 2019, 20, 11-24.	1.8	23

#	ARTICLE	IF	CITATIONS
73	Assigning articles to specific journal issues in the era of the Internet. International Journal of Clinical Practice, 2019, 73, e13310.	1.7	1
74	International Journal of Clinical Practice: What was hot in 2018?. International Journal of Clinical Practice, 2019, 73, e13298.	1.7	0
75	New Mechanisms, New Opportunities. Journal of Clinical Psychiatry, 2019, 80, .	2.2	0
76	Olanzapine Plus Samidorphan in Subjects with Schizophrenia and Comorbid Alcohol Use Disorder: Rationale and Design for a Phase II, Double-blind, Randomized Study. Innovations in Clinical Neuroscience, 2019, 16, 15-21.	0.1	4
77	Perspectives, Commentaries, Consensus Reports, Grand Rounds, Meta-Analyses, Systematic Reviews, Narrative Reviews: Collecting useful information in one place. International Journal of Clinical Practice, 2018, 72, e13079.	1.7	0
78	Reprint of: Clinical management of tardive dyskinesia: Five steps to success. Journal of the Neurological Sciences, 2018, 389, 61-66.	0.6	6
79	Lisdexamfetamine: chemistry, pharmacodynamics, pharmacokinetics, and clinical efficacy, safety, and tolerability in the treatment of binge eating disorder. Expert Opinion on Drug Metabolism and Toxicology, 2018, 14, 229-238.	3.3	26
80	Our digital world: Are monthly issues anachronistic?. International Journal of Clinical Practice, 2018, 72, e13067.	1.7	1
81	Tardive dyskinesia: placing vesicular monoamine transporter type 2 (VMAT2) inhibitors into clinical perspective. Expert Review of Neurotherapeutics, 2018, 18, 323-332.	2.8	15
82	Effect of aripiprazole lauroxil in patients with acute schizophrenia as assessed by the Positive and Negative Syndrome Scale—supportive analyses from a Phase 3 study. CNS Spectrums, 2018, 23, 284-290.	1.2	9
83	Pimavanserin for the treatment of Parkinson’s disease psychosis: number needed to treat, number needed to harm, and likelihood to be helped or harmed. CNS Spectrums, 2018, 23, 228-238.	1.2	13
84	Psychiatric commentary addressing the article titled “Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson’s disease psychosis: an expert consensus” CNS Spectrums, 2018, 23, 355-357.	1.2	0
85	Happy Birthday Ignaz Semmelweis! Now, Let's All Wash Our Hands!. International Journal of Clinical Practice, 2018, 72, e13256.	1.7	3
86	Return to the planet of the apps. International Journal of Clinical Practice, 2018, 72, e13241.	1.7	2
87	Are articles labelled as “Editor’s Choice” downloaded more?. International Journal of Clinical Practice, 2018, 72, e13284.	1.7	2
88	An interview with David L. Streiner: Truth teller of statistical concepts in medicine. International Journal of Clinical Practice, 2018, 72, e13264.	1.7	0
89	152 Pimavanserin for the Treatment of Parkinson’s Disease Psychosis: Number Needed to Treat, Number Needed to Harm, and Likelihood to Be Helped or Harmed. CNS Spectrums, 2018, 23, 94-95.	1.2	0
90	Cariprazine for acute and maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy. Neuropsychiatric Disease and Treatment, 2018, Volume 14, 2563-2577.	2.2	34

#	ARTICLE	IF	CITATIONS
91	Relapse prevention: a cost-effectiveness analysis of brexpiprazole treatment in adult patients with schizophrenia in the USA. <i>ClinicoEconomics and Outcomes Research</i> , 2018, Volume 10, 443-456.	1.9	13
92	Vesicular monoamine transporter type 2 inhibition can lead to effective and tolerable management of tardive dyskinesia. <i>Evidence-Based Mental Health</i> , 2018, 21, e12-e12.	4.5	0
93	Rewarding reviewers, part II: Receiving CME credit. <i>International Journal of Clinical Practice</i> , 2018, 72, e13214.	1.7	0
94	Summer reading: Medicine, psychoanalysis and the zombie apocalypse in comic books. <i>International Journal of Clinical Practice</i> , 2018, 72, e13221.	1.7	3
95	Antipsychotic-Related Movement Disorders: Drug-Induced Parkinsonism vs. Tardive Dyskinesia—Key Differences in Pathophysiology and Clinical Management. <i>Neurology and Therapy</i> , 2018, 7, 233-248.	3.2	73
96	Disclosures: Full transparency is required. <i>International Journal of Clinical Practice</i> , 2018, 72, e13097.	1.7	0
97	Why all the fuss about metabolic syndrome?. <i>International Journal of Clinical Practice</i> , 2018, 72, e13244.	1.7	1
98	Rewarding reviewers, part I: Contributing an editorial. <i>International Journal of Clinical Practice</i> , 2018, 72, e13210.	1.7	2
99	Relationships between clinical scales and binge eating days in adults with moderate to severe binge eating disorder in two Phase III studies. <i>Neuropsychiatric Disease and Treatment</i> , 2018, Volume 14, 537-546.	2.2	6
100	Three free web resources for clinicians and authors. <i>International Journal of Clinical Practice</i> , 2018, 72, e13218.	1.7	0
101	Sustained-Release Risperidone via Subcutaneous Injection: A Systematic Review of RBP-7000 (PERSERIS [®]) for the Treatment of Schizophrenia. <i>Clinical Schizophrenia and Related Psychoses</i> , 2018, 12, 130-141.	1.4	175
102	Inaccurate Prescribing Warnings in Electronic Medical Record Systems. <i>Journal of Clinical Psychiatry</i> , 2018, 80, .	2.2	1
103	Investigational drugs in recent clinical trials for treatment-resistant depression. <i>Expert Review of Neurotherapeutics</i> , 2017, 17, 593-609.	2.8	65
104	Measurement of agitation and aggression in adult and aged neuropsychiatric patients: review of definitions and frequently used measurement scales. <i>CNS Spectrums</i> , 2017, 22, 407-414.	1.2	19
105	Our digital world: Goodbye pagination, hello eLocators!. <i>International Journal of Clinical Practice</i> , 2017, 71, e12928.	1.7	2
106	Virtually yours: Curated collections of articles. <i>International Journal of Clinical Practice</i> , 2017, 71, e12940.	1.7	0
107	Activating and Sedating Adverse Effects of Second-Generation Antipsychotics in the Treatment of Schizophrenia and Major Depressive Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2017, 37, 138-147.	1.4	67
108	Valbenazine for tardive dyskinesia: A systematic review of the efficacy and safety profile for this newly approved novel medication—What is the number needed to treat, number needed to harm and likelihood to be helped or harmed?. <i>International Journal of Clinical Practice</i> , 2017, 71, e12964.	1.7	27

#	ARTICLE	IF	CITATIONS
109	Efficacy of lurasidone in the treatment of agitation: A post hoc analysis of five short-term studies in acutely ill patients with schizophrenia. <i>General Hospital Psychiatry</i> , 2017, 47, 75-82.	2.4	10
110	What to watch in medicine in 2017: Hot topics. <i>International Journal of Clinical Practice</i> , 2017, 71, e12933.	1.7	2
111	Aripiprazole Lauroxil. <i>Journal of Clinical Psychopharmacology</i> , 2017, 37, 289-295.	1.4	47
112	Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology. <i>American Journal of Psychiatry</i> , 2017, 174, 216-229.	7.2	685
113	Authorship: Musings about guests and ghosts. <i>International Journal of Clinical Practice</i> , 2017, 71, e12986.	1.7	2
114	Reducing harms: Focus on drug-drug interactions and adverse drug events. <i>International Journal of Clinical Practice</i> , 2017, 71, e13036.	1.7	0
115	Deutetrabenazine for tardive dyskinesia: A systematic review of the efficacy and safety profile for this newly approved novel medication-What is the number needed to treat, number needed to harm and likelihood to be helped or harmed?. <i>International Journal of Clinical Practice</i> , 2017, 71, e13030.	1.7	28
116	Goodbye Physiciansâ€™ Desk Reference, hello Prescribersâ€™ Digital Reference!. <i>International Journal of Clinical Practice</i> , 2017, 71, e12992.	1.7	1
117	Long-acting injectable antipsychotics update: lengthening the dosing interval and expanding the diagnostic indications. <i>Expert Review of Neurotherapeutics</i> , 2017, 17, 1029-1043.	2.8	23
118	Pharmacologic Treatment of Agitation. , 2017, , 200-218.		1
119	The scourge of uromycitosis and fake journals. <i>International Journal of Clinical Practice</i> , 2017, 71, e12978.	1.7	1
120	Clinical management of tardive dyskinesia: Five steps to success. <i>Journal of the Neurological Sciences</i> , 2017, 383, 199-204.	0.6	11
121	Simplifying medication administration: From daily ingestion to monthly injection. <i>International Journal of Clinical Practice</i> , 2017, 71, e13021.	1.7	0
122	Pharmacokinetics and Pharmacodynamics of Lurasidone Hydrochloride, a Second-Generation Antipsychotic: A Systematic Review of the Published Literature. <i>Clinical Pharmacokinetics</i> , 2017, 56, 493-503.	3.5	40
123	The case for publishing case reports. <i>International Journal of Clinical Practice</i> , 2017, 71, e13043.	1.7	3
124	Introducing images in medicine and grand rounds. <i>International Journal of Clinical Practice</i> , 2017, 71, e13047.	1.7	1
125	Binge-Eating Disorder and Comorbid Conditions. <i>Journal of Clinical Psychiatry</i> , 2017, 78, 9-13.	2.2	23
126	Effects of asenapine on agitation and hostility in adults with acute manic or mixed episodes associated with bipolar I disorder. <i>Neuropsychiatric Disease and Treatment</i> , 2017, Volume 13, 2955-2963.	2.2	7

#	ARTICLE	IF	CITATIONS
127	Required reading to remain relevant. International Journal of Clinical Practice, 2017, 71, e12965.	1.7	1
128	Dr Correll and Colleagues Reply. Journal of Clinical Psychiatry, 2017, 78, e1062.	2.2	1
129	Sensitive and Personalized Determinations of Likelihood of Being Helped or Harmed. Journal of Clinical Psychiatry, 2017, 78, e554-e554.	2.2	0
130	Characteristics of binge eating disorder in relation to diagnostic criteria. Neuropsychiatric Disease and Treatment, 2016, Volume 12, 2213-2223.	2.2	38
131	Schizophrenia relapse, patient considerations, and potential role of lurasidone. Patient Preference and Adherence, 2016, Volume 10, 1529-1537.	1.8	11
132	Managing Agitation Associated with Schizophrenia and Bipolar Disorder in the Emergency Setting. Western Journal of Emergency Medicine, 2016, 17, 165-172.	1.1	47
133	Categorical improvements in disease severity in patients with major depressive disorder treated with vilazodone: post hoc analysis of four randomized, placebo-controlled trials. Neuropsychiatric Disease and Treatment, 2016, Volume 12, 3073-3081.	2.2	0
134	Effect of aripiprazole lauroxil on agitation and hostility in patients with schizophrenia. International Clinical Psychopharmacology, 2016, 31, 69-75.	1.7	21
135	The effect of brexpiprazole (OPC-34712) and aripiprazole in adult patients with acute schizophrenia. International Clinical Psychopharmacology, 2016, 31, 192-201.	1.7	46
136	More inclusive bipolar mixed depression definition by permitting overlapping and non-overlapping mood elevation symptoms. Acta Psychiatrica Scandinavica, 2016, 134, 199-206.	4.5	19
137	Perceptions matter: Attitudes and health outcomes. International Journal of Clinical Practice, 2016, 70, 966-966.	1.7	0
138	NNT and NNH remain helpful in evidence-based medicine. British Journal of Psychiatry, 2016, 209, 262-263.	2.8	2
139	Emerging pharmacological therapies in schizophrenia: what's new, what's different, what's next?. CNS Spectrums, 2016, 21, 1-12.	1.2	14
140	Which role for brexpiprazole, a new dopamine D2 partial agonist, in the treatment of schizophrenia?. Evidence-Based Mental Health, 2016, 19, e6-e6.	4.5	1
141	Investigational drugs for treating agitation in persons with dementia. Expert Opinion on Investigational Drugs, 2016, 25, 973-983.	4.1	25
142	What's in a name? Use of brand vs. generic drug names. International Journal of Clinical Practice, 2016, 70, 3-4.	1.7	1
143	Breakthrough drugs for the interface between psychiatry and neurology. International Journal of Clinical Practice, 2016, 70, 298-299.	1.7	6
144	Peer review and Publons - enhancements for the reviewer. International Journal of Clinical Practice, 2016, 70, 364-364.	1.7	6

#	ARTICLE	IF	CITATIONS
145	How do I get my manuscript accepted? Steps and missteps. <i>International Journal of Clinical Practice</i> , 2016, 70, 97-98.	1.7	0
146	Rosacea and dementia: relative vs. absolute effect sizes. <i>International Journal of Clinical Practice</i> , 2016, 70, 428-429.	1.7	0
147	The grey literature is far from drab. <i>International Journal of Clinical Practice</i> , 2016, 70, 790-790.	1.7	4
148	Open researcher and contributor ID: ORCID now mandatory for Wiley journals. <i>International Journal of Clinical Practice</i> , 2016, 70, 884-885.	1.7	5
149	Recommendations to improve adverse event reporting in clinical trial publications: a joint pharmaceutical industry/journal editor perspective. <i>BMJ</i> , The, 2016, 355, i5078.	6.0	70
150	Food for thought: do you ask about eating?. <i>International Journal of Clinical Practice</i> , 2016, 70, 516-517.	1.7	3
151	More food for thought: preferred words. <i>International Journal of Clinical Practice</i> , 2016, 70, 640-640.	1.7	2
152	From banknotes to people: one million is impressive. <i>International Journal of Clinical Practice</i> , 2016, 70, 702-703.	1.7	0
153	More inclusive bipolar mixed depression definitions by requiring fewer non-overlapping mood elevation symptoms. <i>Acta Psychiatrica Scandinavica</i> , 2016, 134, 189-198.	4.5	11
154	Hostility in schizophrenia: An integrated analysis of the combined Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and the European First Episode Schizophrenia Trial (EUFEST) studies. <i>European Psychiatry</i> , 2016, 31, 13-19.	0.2	17
155	Aripiprazole long-acting injectable formulations for schizophrenia: aripiprazole monohydrate and aripiprazole lauroxil. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 169-186.	3.1	28
156	Zika and You. <i>International Journal of Clinical Practice</i> , 2016, 70, 181-182.	1.7	1
157	Therapeutic improvements expected in the near future for schizophrenia and schizoaffective disorder: an appraisal of phase III clinical trials of schizophrenia-targeted therapies as found in US and EU clinical trial registries. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 921-936.	1.8	26
158	Vortioxetine for major depressive disorder: An indirect comparison with duloxetine, escitalopram, levomilnacipran, sertraline, venlafaxine, and vilazodone, using number needed to treat, number needed to harm, and likelihood to be helped or harmed. <i>Journal of Affective Disorders</i> , 2016, 196, 225-233.	4.1	51
159	Cariprazine for the Treatment of Schizophrenia: A Review of this Dopamine D3-Preferring D3/D2 Receptor Partial Agonist. <i>Clinical Schizophrenia and Related Psychoses</i> , 2016, 10, 109-119.	1.4	38
160	Guide to the Management of Clozapine-Related Tolerability and Safety Concerns. <i>Clinical Schizophrenia and Related Psychoses</i> , 2016, 10, 163-177.	1.4	73
161	Brexipiprazole for the Treatment of Schizophrenia: A Review of this Novel Serotonin-Dopamine Activity Modulator. <i>Clinical Schizophrenia and Related Psychoses</i> , 2016, 9, 177-186.	1.4	24
162	A Guide to the Management of Clozapine-Related Tolerability and Safety Concerns. <i>Clinical Schizophrenia and Related Psychoses</i> , 2016, , .	1.4	4

#	ARTICLE	IF	CITATIONS
163	The Use of Long-Acting Injectable Antipsychotics in Schizophrenia. Journal of Clinical Psychiatry, 2016, 77, 1-24.	2.2	267
164	The Effect of Cariprazine on Hostility Associated With Schizophrenia. Journal of Clinical Psychiatry, 2016, 77, 109-115.	2.2	33
165	Lurasidone Dose Escalation in Early Nonresponding Patients With Schizophrenia. Journal of Clinical Psychiatry, 2016, 77, 1672-1680.	2.2	30
166	Pharmaceutical Innovation in the Treatment of Schizophrenia and Mental Disorders Compared with Other Diseases. Innovations in Clinical Neuroscience, 2016, 13, 17-25.	0.1	14
167	A primer on binge eating disorder diagnosis and management. CNS Spectrums, 2015, 20, 41-51.	1.2	17
168	Cognitive impairment in schizophrenia: the great unmet need. CNS Spectrums, 2015, 20, 32-40.	1.2	22
169	Partial and non-adherence: we need all the help we can get. International Journal of Clinical Practice, 2015, 69, 1-2.	1.7	4
170	Lisdexamfetamine for binge eating disorder in adults: a systematic review of the efficacy and safety profile for this newly approved indication - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?. International Journal of Clinical Practice, 2015, 69, 410-421.	1.7	92
171	Medical photography: it has never been so easy and yet so complex. International Journal of Clinical Practice, 2015, 69, 387-387.	1.7	3
172	What is good publication practice, what is ISMPP, and why you should care. International Journal of Clinical Practice, 2015, 69, 913-914.	1.7	5
173	Conflicts of interest: a matter of transparency. International Journal of Clinical Practice, 2015, 69, 267-268.	1.7	0
174	Transdermal patches: how common are application site reactions and how severe are they?. International Journal of Clinical Practice, 2015, 69, 509-510.	1.7	0
175	My two favourite professional social networking sites: LinkedIn and ResearchGate - how they can help you, or hurt you. International Journal of Clinical Practice, 2015, 69, 623-624.	1.7	15
176	Moving forward with article level metrics: introducing altmetrics. International Journal of Clinical Practice, 2015, 69, 811-811.	1.7	23
177	Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic - what is the number needed to treat, number needed to harm and likelihood to be hel. International Journal of Clinical Practice, 2015, 69, 978-997.	1.7	53
178	Access to the biomedical literature: beyond the paywall. International Journal of Clinical Practice, 2015, 69, 1031-1031.	1.7	3
179	The ABC's of dopamine receptor partial agonists - aripiprazole, brexpiprazole and cariprazine: the 15-min challenge to sort these agents out. International Journal of Clinical Practice, 2015, 69, 1211-1220.	1.7	80
180	An evidence-based medicine field guide to new and current psychotropic medications and related drugs: a virtual issue of the International Journal of Clinical Practice. International Journal of Clinical Practice, 2015, 69, 1393-1395.	1.7	0

#	ARTICLE	IF	CITATIONS
181	Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP3. <i>Annals of Internal Medicine</i> , 2015, 163, 461-464.	3.9	291
182	Treatment of early non-response in patients with schizophrenia: assessing the efficacy of antipsychotic dose escalation. <i>BMC Psychiatry</i> , 2015, 15, 271.	2.6	13
183	THE AMERICAN SOCIETY OF CLINICAL PSYCHOPHARMACOLOGY SURVEY OF PSYCHOPHARMACOLOGISTS'S PRACTICE PATTERNS FOR THE TREATMENT OF MOOD DISORDERS. <i>Depression and Anxiety</i> , 2015, 32, 605-613.	4.1	34
184	Lack of tolerable treatment options for patients with schizophrenia. <i>Neuropsychiatric Disease and Treatment</i> , 2015, 11, 3095.	2.2	17
185	Pharmacotherapy for bipolar depression: comparative efficacy and acceptability is in the eye of the beholder. <i>Evidence-Based Mental Health</i> , 2015, 18, 88-88.	4.5	2
186	Switching to loperidone. <i>Clinical Schizophrenia and Related Psychoses</i> , 2015, 8, 183-195.	1.4	6
187	Liraglutide subcutaneous injection for weight loss: where does it fit?. <i>International Journal of Clinical Practice</i> , 2015, 69, 719-721.	1.7	1
188	Vilazodone, levomilnacipran and vortioxetine for major depressive disorder: the 15-min challenge to sort these agents out. <i>International Journal of Clinical Practice</i> , 2015, 69, 151-155.	1.7	10
189	Treatment adherence in schizophrenia: A patient-level meta-analysis of combined CATIE and EUFEST studies. <i>European Neuropsychopharmacology</i> , 2015, 25, 1158-1166.	0.7	84
190	Preventing Violence in Patients with Schizophrenia. <i>Current Treatment Options in Psychiatry</i> , 2015, 2, 182-191.	1.9	4
191	Paliperidone Palmitate for Schizoaffective Disorder: A Review of the Clinical Evidence. <i>Neurology and Therapy</i> , 2015, 4, 81-91.	3.2	15
192	Evaluating the efficacy of vilazodone in achieving remission in patients with major depressive disorder. <i>International Clinical Psychopharmacology</i> , 2015, 30, 75-81.	1.7	7
193	Patients' Preferences Related to Benefits, Risks, and Formulations of Schizophrenia Treatment. <i>Psychiatric Services</i> , 2015, 66, 719-726.	2.0	28
194	The preclinical profile of brexpiprazole: what is its clinical relevance for the treatment of psychiatric disorders?. <i>Expert Review of Neurotherapeutics</i> , 2015, 15, 1219-1229.	2.8	45
195	P.3.d.073 Cariprazine and the reduction of hostility associated with schizophrenia. <i>European Neuropsychopharmacology</i> , 2015, 25, S523.	0.7	0
196	Lurasidone: a novel antipsychotic agent for the treatment of schizophrenia and bipolar depression. <i>BJPsych Bulletin</i> , 2015, 39, 237-241.	1.1	39
197	Brexpiprazole: a new dopamine D2 receptor partial agonist for the treatment of schizophrenia and major depressive disorder. <i>Drugs of Today</i> , 2015, 51, 397.	1.1	24
198	Number Needed to Treat Can Be Helpful. <i>Journal of Clinical Psychiatry</i> , 2015, 76, e1136-e1136.	2.2	0

#	ARTICLE	IF	CITATIONS
199	Balancing benefits and harms of treatments for acute bipolar depression. <i>Journal of Affective Disorders</i> , 2014, 169, S24-S33.	4.1	41
200	Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: a 6-month, open-label, extension study. <i>CNS Spectrums</i> , 2014, 19, 330-339.	1.2	38
201	Cost-effectiveness of aripiprazole once-monthly compared with paliperidone palmitate once-monthly injectable for the treatment of schizophrenia in the United States. <i>Journal of Medical Economics</i> , 2014, 17, 567-576.	2.1	25
202	Psychiatrists'™ Judgments About Antipsychotic Benefit and Risk Outcomes and Formulation in Schizophrenia Treatment. <i>Psychiatric Services</i> , 2014, 65, 1133-1139.	2.0	7
203	Physician heal thyself: adventures in hypertension. <i>International Journal of Clinical Practice</i> , 2014, 68, 1283-1283.	1.7	2
204	Are you a Sunshine Superman? The US Sunshine Act and reporting requirements. <i>International Journal of Clinical Practice</i> , 2014, 68, 1175-1176.	1.7	1
205	Ride â€™em cowboy! The therapeutics of virtual reality technology and simulation. <i>International Journal of Clinical Practice</i> , 2014, 68, 931-931.	1.7	2
206	Paging Dr Cohen, Paging Dr Cohenâ€™ An effect size interpretation is required STAT!. <i>International Journal of Clinical Practice</i> , 2014, 68, 533-534.	1.7	22
207	Suvorexant for insomnia: a systematic review of the efficacy and safety profile for this newly approved hypnotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?. <i>International Journal of Clinical Practice</i> , 2014, 68, 1429-1441.	1.7	231
208	Pharmaism: a tale of two perspectives. <i>International Journal of Clinical Practice</i> , 2014, 68, 659-661.	1.7	7
209	Where do peer reviewers come from?. <i>International Journal of Clinical Practice</i> , 2014, 68, 793-793.	1.7	3
210	Where do editorials come from?. <i>International Journal of Clinical Practice</i> , 2014, 68, 285-285.	1.7	2
211	Vortioxetine for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?. <i>International Journal of Clinical Practice</i> , 2014, 68, 60-82.	1.7	84
212	Where do accepted journal manuscripts come from?. <i>International Journal of Clinical Practice</i> , 2014, 68, 1049-1050.	1.7	1
213	A singleâ€™dose, randomized, doubleâ€™blind, placeboâ€™controlled trial of sublingual asenapine for acute agitation. <i>Acta Psychiatrica Scandinavica</i> , 2014, 130, 61-68.	4.5	59
214	Lorcaserin, phentermine topiramate combination, and naltrexone bupropion combination for weight loss: the 15-min challenge to sort these agents out. <i>International Journal of Clinical Practice</i> , 2014, 68, 1401-1405.	1.7	10
215	The slow death of print. <i>International Journal of Clinical Practice</i> , 2014, 68, 1-1.	1.7	2
216	Treatment of bipolar depression: making sensible decisions. <i>CNS Spectrums</i> , 2014, 19, 1-12.	1.2	13

#	ARTICLE	IF	CITATIONS
217	Effectiveness of antipsychotic drugs against hostility in patients with schizophrenia in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study. <i>CNS Spectrums</i> , 2014, 19, 374-381.	1.2	33
218	A review of real-world data on the effects of aripiprazole on weight and metabolic outcomes in adults. <i>Current Medical Research and Opinion</i> , 2014, 30, 1629-1641.	1.9	34
219	Review: 15 antipsychotic drugs are more effective than placebo for the treatment of schizophrenia, but vary in their tolerability. <i>Evidence-Based Mental Health</i> , 2014, 17, 9-9.	4.5	5
220	The psychopharmacology of violence: making sensible decisions. <i>CNS Spectrums</i> , 2014, 19, 411-418.	1.2	56
221	Clinical assessment of lurasidone benefit and risk in the treatment of bipolar I depression using number needed to treat, number needed to harm, and likelihood to be helped or harmed. <i>Journal of Affective Disorders</i> , 2014, 155, 20-27.	4.1	58
222	Formulations: friendly, fast, forgiving and flexible. <i>International Journal of Clinical Practice</i> , 2014, 68, 407-407.	1.7	2
223	Battle for the planet of the apps. <i>International Journal of Clinical Practice</i> , 2014, 68, 141-142.	1.7	1
224	Asenapine review, part I: chemistry, receptor affinity profile, pharmacokinetics and metabolism. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2014, 10, 893-903.	3.3	54
225	Asenapine review, part II: clinical efficacy, safety and tolerability. <i>Expert Opinion on Drug Safety</i> , 2014, 13, 1-28.	2.4	34
226	A trial evaluating gradual- or immediate-switch strategies from risperidone, olanzapine, or aripiprazole to iloperidone in patients with schizophrenia. <i>Schizophrenia Research</i> , 2014, 153, 160-168.	2.0	15
227	Effectiveness of antipsychotic drugs against hostility in patients with schizophrenia in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study – ADDENDUM. <i>CNS Spectrums</i> , 2014, 19, 466-466.	1.2	4
228	Prevalence of Pre-Existing Risk Factors for Adverse Events Associated with Atypical Antipsychotics Among Commercially Insured and Medicaid Insured Patients Newly Initiating Atypical Antipsychotics. <i>Current Drug Safety</i> , 2014, 9, 227-235.	0.6	8
229	Unmet Needs in the Treatment of Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2014, 75, 21-26.	2.2	73
230	New Treatment Targets to Improve Symptoms in Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2014, 75, e22.	2.2	3
231	Psicofarmacologia e terapia elettroconvulsivante. , 2014, , 271-289.		0
232	The Sunshine Act and Transfers of Value: Impact on Non-industry Authorship. <i>Innovations in Clinical Neuroscience</i> , 2014, 11, 14-6.	0.1	2
233	Quantifying clinical relevance. <i>Innovations in Clinical Neuroscience</i> , 2014, 11, 26-30.	0.1	25
234	Beyond PubMed: Searching the "Grey Literature" for Clinical Trial Results. <i>Innovations in Clinical Neuroscience</i> , 2014, 11, 42-6.	0.1	8

#	ARTICLE	IF	CITATIONS
235	A Review of the Pharmacology, Efficacy and Tolerability of Recently Approved and Upcoming Oral Antipsychotics: An Evidence-Based Medicine Approach. <i>CNS Drugs</i> , 2013, 27, 879-911.	5.9	79
236	A systematic review of psychostimulant treatment of negative symptoms of schizophrenia: Challenges and therapeutic opportunities. <i>Schizophrenia Research</i> , 2013, 147, 241-252.	2.0	81
237	Diagnoses Associated With Use of Atypical Antipsychotics in a Commercial Health Plan: A Claims Database Analysis. <i>Clinical Therapeutics</i> , 2013, 35, 1867-1875.	2.5	28
238	Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2013, 9, 193-206.	3.3	106
239	Levomilnacipran for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?. <i>International Journal of Clinical Practice</i> , 2013, 67, 1089-1104.	1.7	199
240	Cariprazine in Bipolar Disorder: Clinical Efficacy, Tolerability, and Place in Therapy. <i>Advances in Therapy</i> , 2013, 30, 102-113.	2.9	34
241	Cariprazine in Schizophrenia: Clinical Efficacy, Tolerability, and Place in Therapy. <i>Advances in Therapy</i> , 2013, 30, 114-126.	2.9	51
242	P.2.b.018 Post hoc analyses of levomilnacipran SR 40, 80, and 120 mg on functional outcomes in major depressive disorder. <i>European Neuropsychopharmacology</i> , 2013, 23, S329.	0.7	2
243	P.3.d.007 Efficacy of cariprazine on PANSS items and Marder factors: post hoc analysis of a double-blind, placebo-controlled trial in schizophrenia. <i>European Neuropsychopharmacology</i> , 2013, 23, S461-S462.	0.7	0
244	Number needed to treat can be helpful: A response to Alphas et al.. <i>European Neuropsychopharmacology</i> , 2013, 23, 1656-1657.	0.7	2
245	Placing transdermal selegiline for major depressive disorder into clinical context: Number needed to treat, number needed to harm, and likelihood to be helped or harmed. <i>Journal of Affective Disorders</i> , 2013, 151, 409-417.	4.1	18
246	“Meta-guidelines” for the management of patients with schizophrenia. <i>CNS Spectrums</i> , 2013, 18, 150-162.	1.2	61
247	Number Needed to Harm Can Be Clinically Useful. <i>Journal of Nervous and Mental Disease</i> , 2013, 201, 1001-1002.	1.0	1
248	High-Dose Oral Ziprasidone Versus Conventional Dosing in Schizophrenia Patients With Residual Symptoms. <i>Journal of Clinical Psychopharmacology</i> , 2013, 33, 485-490.	1.4	19
249	Review: limited evidence on effects of haloperidol alone for rapid tranquillisation in psychosis-induced aggression. <i>Evidence-Based Mental Health</i> , 2013, 16, 47-47.	4.5	3
250	Preserving books by destroying them: a foray into digitization of a professional library. <i>International Journal of Clinical Practice</i> , 2013, 67, 927-929.	1.7	2
251	Meta-analyses: editor's dream or nightmare?. <i>International Journal of Clinical Practice</i> , 2013, 67, 1069-1070.	1.7	6
252	When does a difference make a difference? Interpretation of number needed to treat, number needed to harm, and likelihood to be helped or harmed. <i>International Journal of Clinical Practice</i> , 2013, 67, 407-411.	1.7	193

#	ARTICLE	IF	CITATIONS
253	How we rate: is impact factor the most important measure?. International Journal of Clinical Practice, 2013, 67, 819-820.	1.7	6
254	Back to the future: transitions, technology and tao. International Journal of Clinical Practice, 2013, 67, 701-702.	1.7	1
255	New second-generation long-acting injectable antipsychotics for the treatment of schizophrenia. Expert Review of Neurotherapeutics, 2013, 13, 767-783.	2.8	73
256	Holiday time! evidence-based flying revisited. International Journal of Clinical Practice, 2013, 67, 1213-1214.	1.7	0
257	Addressing the need for rapid treatment of agitation in schizophrenia and bipolar disorder: focus on inhaled loxapine as an alternative to injectable agents. Therapeutics and Clinical Risk Management, 2013, 9, 235.	2.0	34
258	Effectiveness of Lurasidone in Patients with Schizophrenia or Schizoaffective Disorder Switched From Other Antipsychotics. Journal of Clinical Psychiatry, 2013, 74, 170-179.	2.2	56
259	Incidence of Cardiovascular Outcomes and Diabetes Mellitus Among Users of Second-Generation Antipsychotics. Journal of Clinical Psychiatry, 2013, 74, 1199-1206.	2.2	28
260	A General Treatment Approach. , 2013, , 14-19.		0
261	Psychopharmacological Approaches. , 2013, , 37-56.		0
262	Somatic Treatments. , 2013, , 57-60.		0
263	Adherence: The Great Masquerader of Treatment-Resistance. , 2013, , 20-28.		0
264	Dosing of Antipsychotics: What Evidence Do We Use?. , 2013, , 29-33.		0
265	Long-term safety and tolerability of lurasidone in schizophrenia. International Clinical Psychopharmacology, 2012, 27, 165-176.	1.7	101
266	A Systematic Review of Duloxetine for Osteoarthritic Pain: What is the Number Needed to Treat, Number Needed to Harm, and Likelihood to be Helped or Harmed?. Postgraduate Medicine, 2012, 124, 83-93.	2.0	39
267	Interview: The future of psychiatric medicine: clinical trials and beyond. Clinical Practice (London,) Tj ETQq1 1 0.784314 rgBT 0 Overlo		
268	Oral paliperidone extended-release: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability. Expert Opinion on Drug Metabolism and Toxicology, 2012, 8, 873-888.	3.3	24
269	A systematic review of meta-analyses of the efficacy of oral atypical antipsychotics for the treatment of adult patients with schizophrenia. Expert Opinion on Pharmacotherapy, 2012, 13, 1545-1573.	1.8	52
270	Lurasidone for schizophrenia: whatâ€™s different?. Expert Review of Neurotherapeutics, 2012, 12, 265-273.	2.8	11

#	ARTICLE	IF	CITATIONS
271	A clinician's best friend: the US National Library of Medicine's patient resources. <i>International Journal of Clinical Practice</i> , 2012, 66, 1018-1019.	1.7	1
272	Addressing challenges in bipolar diagnosis: what do good clinicians already do?. <i>Acta Psychiatrica Scandinavica</i> , 2012, 126, 393-394.	4.5	2
273	Antidepressant Therapy for Pain Associated With Osteoarthritis. <i>PM and R</i> , 2012, 4, 1024-1025.	1.6	0
274	Impact of the CATIE trial on antipsychotic prescribing. <i>Schizophrenia Research</i> , 2012, 138, 295.	2.0	0
275	Oral Antipsychotic Update: A Brief Review of New and Investigational Agents for the Treatment of Schizophrenia. <i>CNS Spectrums</i> , 2012, 17, 1-9.	1.2	9
276	Lurasidone in Schizophrenia: New Information About Dosage and Place in Therapy. <i>Advances in Therapy</i> , 2012, 29, 815-825.	2.9	32
277	On-label on the table: what the package insert informs us about the tolerability profile of oral atypical antipsychotics, and what it does not. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 1599-1613.	1.8	24
278	Inhaled loxapine for agitation revisited: focus on effect sizes from 2 Phase III randomised controlled trials in persons with schizophrenia or bipolar disorder. <i>International Journal of Clinical Practice</i> , 2012, 66, 318-325.	1.7	32
279	Vilazodone for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?. <i>International Journal of Clinical Practice</i> , 2012, 66, 356-368.	1.7	220
280	Antidepressants and the relief of osteoarthritic pain - Findings from a study examining adjunctive duloxetine. <i>International Journal of Clinical Practice</i> , 2012, 66, 431-433.	1.7	6
281	Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials. <i>Human Psychopharmacology</i> , 2012, 27, 24-32.	1.5	15
282	Lurasidone for the Acute Treatment of Adults with Schizophrenia: What is the Number Needed to Treat, Number Needed to Harm, and Likelihood to be Helped or Harmed?. <i>Clinical Schizophrenia and Related Psychoses</i> , 2012, 6, 76-85.	1.4	32
283	Trends in combination antipsychotic use among persons with commercial insurance: a data snapshot. <i>Innovations in Clinical Neuroscience</i> , 2012, 9, 17-8.	0.1	0
284	Olanzapine-fluoxetine combination for the treatment of bipolar depression. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 2751-2758.	1.8	17
285	Pharmacological Management of Acute and Persistent Aggression in Forensic Psychiatry Settings. <i>CNS Drugs</i> , 2011, 25, 1009-1021.	5.9	40
286	Drug safety evaluation of ziprasidone. <i>Expert Opinion on Drug Safety</i> , 2011, 10, 437-448.	2.4	22
287	Treatment-refractory schizophrenia: what is it and what has been done about it?. <i>Neuropsychiatry</i> , 2011, 1, 325-347.	0.4	10
288	Pathways to Aggression in Schizophrenia Affect Results of Treatment. <i>Schizophrenia Bulletin</i> , 2011, 37, 921-929.	4.3	154

#	ARTICLE	IF	CITATIONS
289	Schizoaffective Disorder. <i>CNS Drugs</i> , 2011, 25, 317-331.	5.9	23
290	Efficacy of iloperidone in schizophrenia: A PANSS five-factor analysis. <i>Schizophrenia Research</i> , 2011, 131, 75-81.	2.0	68
291	Treatment-resistant schizophrenia: What's next. <i>Schizophrenia Research</i> , 2011, 133, 1-2.	2.0	2
292	Weight Gain and Changes in Metabolic Variables following Olanzapine Treatment in Schizophrenia and Bipolar Disorder. <i>Clinical Drug Investigation</i> , 2011, 31, 455-482.	2.2	93
293	High dose quetiapine in the treatment of psychosis due to traumatic brain injury. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2011, 35, 280-281.	4.8	6
294	Role of sublingual asenapine in treatment of schizophrenia. <i>Neuropsychiatric Disease and Treatment</i> , 2011, 7, 325.	2.2	25
295	A Randomized, Double-Blind, Parallel-Group, Fixed-Dose, Clinical Trial of Quetiapine at 600 Versus 1200 mg/d for Patients With Treatment-Resistant Schizophrenia or Schizoaffective Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2011, 31, 160-168.	1.4	29
296	Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic. <i>International Journal of Clinical Practice</i> , 2011, 65, 189-210.	1.7	106
297	Does it work, will it work, and is it worth it? A call for papers (and reviewers) regarding effective treatments for psychiatric disorders. <i>International Journal of Clinical Practice</i> , 2011, 65, 232-233.	1.7	5
298	Aerosolised antipsychotic assuages agitation: inhaled loxapine for agitation associated with schizophrenia or bipolar disorder. <i>International Journal of Clinical Practice</i> , 2011, 65, 330-340.	1.7	31
299	Evidence-based medicine: it's not just about the evidence. <i>International Journal of Clinical Practice</i> , 2011, 65, 634-635.	1.7	20
300	Treatments for bipolar disorder: can number needed to treat/harm help inform clinical decisions?. <i>Acta Psychiatrica Scandinavica</i> , 2011, 123, 175-189.	4.5	42
301	Quantifying Clinical Relevance in Treatments for Psychiatric Disorders. <i>Clinical Therapeutics</i> , 2011, 33, B1-B2.	2.5	2
302	Iloperidone, Asenapine, and Lurasidone: A Brief Overview of 3 New Second-Generation Antipsychotics. <i>Postgraduate Medicine</i> , 2011, 123, 153-162.	2.0	54
303	Psychopharmacology of Aggression in Schizophrenia. <i>Schizophrenia Bulletin</i> , 2011, 37, 930-936.	4.3	37
304	The Tyranny of the P-value: Effect Size Matters. <i>Journal of Microbiology and Biotechnology</i> , 2011, 21, 91-92.	2.1	8
305	Lurasidone for Schizophrenia: A Brief Review of a New Second-Generation Antipsychotic. <i>Clinical Schizophrenia and Related Psychoses</i> , 2011, 4, 251-257.	1.4	44
306	Iloperidone. <i>Journal of Clinical Psychiatry</i> , 2011, 72, 19-23.	2.2	19

#	ARTICLE	IF	CITATIONS
307	Number Needed to Treat: What It Is and What It Isn't, and Why Every Clinician Should Know How to Calculate It. <i>Journal of Clinical Psychiatry</i> , 2011, 72, 412-413.	2.2	30
308	Psychiatric Illness, Psychotropic Medication, and Childhood Obesity. , 2011, , 265-277.		0
309	Likelihood to Be Helped or Harmed Can Assist in Clinical Decision-Making. <i>Journal of Clinical Psychiatry</i> , 2011, 72, 261-262.	2.2	0
310	Paliperidone palmitate - review of the efficacy, safety and cost of a new second-generation depot antipsychotic medication. <i>International Journal of Clinical Practice</i> , 2010, 64, 216-239.	1.7	81
311	Datapoints: Depot Antipsychotic Use in New York State Hospitals, 1994 to 2009. <i>Psychiatric Services</i> , 2010, 61, 9-9.	2.0	5
312	Introduction and Overview of the Real World Management of Schizophrenia in the Comorbid Patient. <i>CNS Spectrums</i> , 2010, 15, 3-5.	1.2	0
313	lloperidone: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability, regulatory affairs, and an opinion. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2010, 6, 1551-1564.	3.3	35
314	Spirituality, Schizophrenia, and State Hospitals: Program Description and Characteristics of Self-Selected Attendees of a Spirituality Therapeutic Group. <i>Psychiatric Quarterly</i> , 2010, 81, 285-292.	2.1	30
315	Relative vs. absolute measures of benefit and risk: what's the difference?. <i>Acta Psychiatrica Scandinavica</i> , 2010, 121, 94-102.	4.5	62
316	lloperidone redux: a dissection of the Drug Approval Package for this newly commercialised second-generation antipsychotic. <i>International Journal of Clinical Practice</i> , 2010, 64, 707-718.	1.7	30
317	Evidence-based flying: a new paradigm for frequent flyers. <i>International Journal of Clinical Practice</i> , 2010, 64, 667-668.	1.7	4
318	Nine out of ten doctors prefer Camels! Three brief essays regarding how we use and abuse statistics. <i>International Journal of Clinical Practice</i> , 2010, 64, 997-998.	1.7	2
319	Miracle pills for weight loss: what is the number needed to treat, number needed to harm and likelihood to be helped or harmed for naltrexone-bupropion combination?. <i>International Journal of Clinical Practice</i> , 2010, 64, 1462-1465.	1.7	7
320	Citability of Original Research and Reviews in Journals and Their Sponsored Supplements. <i>PLoS ONE</i> , 2010, 5, e9876.	2.5	11
321	Stimulant-Induced Trichotillomania. <i>Substance Abuse</i> , 2010, 31, 68-70.	2.3	14
322	Ziprasidone HCl capsules for the adjunctive maintenance treatment of bipolar disorder in adults. <i>Expert Review of Neurotherapeutics</i> , 2010, 10, 1031-1037.	2.8	12
323	Adjunctive Aripiprazole, Olanzapine, or Quetiapine for Major Depressive Disorder: An Analysis of Number Needed to Treat, Number Needed to Harm, and Likelihood to be Helped or Harmed. <i>Postgraduate Medicine</i> , 2010, 122, 39-48.	2.0	228
324	Treatment of schizophrenia with depot preparations of fluphenazine, haloperidol, and risperidone among inpatients at state-operated psychiatric facilities. <i>Schizophrenia Research</i> , 2010, 119, 153-159.	2.0	12

#	ARTICLE	IF	CITATIONS
325	The importance of a good night's sleep: An open-label trial of the sodium salt of Î³-hydroxybutyric acid in insomnia associated with schizophrenia. <i>Schizophrenia Research</i> , 2010, 120, 225-226.	2.0	16
326	Authors' Submission Toolkit: A practical guide to getting your research published. <i>Current Medical Research and Opinion</i> , 2010, 26, 1967-1982.	1.9	53
327	How to Efficiently Maintain Your Own Electronic Resource Library. <i>Journal of Clinical Psychiatry</i> , 2010, 71, 207-208.	2.2	0
328	Polypharmacy of schizophrenia. <i>Psychiatry</i> , 2010, 7, 17-9.	0.3	1
329	A review of new atypical antipsychotic launches in the United States. <i>Psychiatry</i> , 2010, 7, 13-5.	0.3	2
330	Patient perspectives in the development and use of long-acting antipsychotics in schizophrenia: focus on olanzapine long-acting injection. <i>Patient Preference and Adherence</i> , 2009, 3, 345.	1.8	17
331	Leslie Citrome. <i>Psychiatric Bulletin</i> , 2009, 33, 400-400.	0.3	0
332	Egg Consumption and Risk of Type 2 Diabetes in Men and Women: Response to Djousse et al.. <i>Diabetes Care</i> , 2009, 32, e73-e73.	8.6	2
333	Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 1917-1928.	1.8	69
334	Quantifying Risk: The Role of Absolute and Relative Measures in Interpreting Risk of Adverse Reactions from Product Labels of Antipsychotic Medications. <i>Current Drug Safety</i> , 2009, 4, 229-237.	0.6	58
335	Teaching the philosophy and tools of evidence-based medicine: misunderstandings and solutions*. <i>Journal of Evidence-Based Medicine</i> , 2009, 2, 220-225.	1.8	2
336	A review of tolerability and abuse liability of Î³-hydroxybutyric acid for insomnia in patients with schizophrenia. <i>Clinical Therapeutics</i> , 2009, 31, 1360-1373.	2.5	12
337	Statins Medication Administration Predicts Hospital Discharge. <i>Psychiatric Quarterly</i> , 2009, 80, 65-73.	2.1	4
338	Staff and Patient Views of the Reasons for Aggressive Incidents: A Prospective, Incident-Based Study. <i>Psychiatric Quarterly</i> , 2009, 80, 167-172.	2.1	19
339	Using oral ziprasidone effectively: the food effect and dose-response. <i>Advances in Therapy</i> , 2009, 26, 739-748.	2.9	43
340	Olanzapine pamoate: a stick in time?. <i>International Journal of Clinical Practice</i> , 2009, 63, 140-150.	1.7	63
341	JUPITER: wake up and smell the coffee - The absolute and relative merits of statin use. <i>International Journal of Clinical Practice</i> , 2009, 63, 347-348.	1.7	8
342	Teaching the philosophy and tools of evidence-based medicine: misunderstandings and solutions. <i>International Journal of Clinical Practice</i> , 2009, 63, 353-359.	1.7	11

#	ARTICLE	IF	CITATIONS
343	Posters can be a sticking point: Letter in response to comments by Akhras etÂal.. International Journal of Clinical Practice, 2009, 63, 963-963.	1.7	0
344	Systematic reviews: much ado about a lot. International Journal of Clinical Practice, 2009, 63, 832-833.	1.7	3
345	lloperidone for schizophrenia: a review of the efficacy and safety profile for this newly commercialised second-generation antipsychotic. International Journal of Clinical Practice, 2009, 63, 1237-1248.	1.7	56
346	How to search and harvest the medical literature: let the citations come to you, and how to proceed when they do. International Journal of Clinical Practice, 2009, 63, 1565-1570.	1.7	27
347	Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic. International Journal of Clinical Practice, 2009, 63, 1762-1784.	1.7	99
348	Dose trends for second-generation antipsychotic treatment of schizophrenia and bipolar disorder. Schizophrenia Research, 2009, 108, 238-244.	2.0	31
349	Effect of ziprasidone dose on all-cause discontinuation rates in acute schizophrenia and schizoaffective disorder: A post-hoc analysis of 4 fixed-dose randomized clinical trials. Schizophrenia Research, 2009, 111, 39-45.	2.0	15
350	Impact of real-world ziprasidone dosing on treatment discontinuation rates in patients with schizophrenia or bipolar disorder. Schizophrenia Research, 2009, 115, 115-120.	2.0	19
351	Adjunctive lithium and anticonvulsants for the treatment of schizophrenia: what is the evidence?. Expert Review of Neurotherapeutics, 2009, 9, 55-71.	2.8	78
352	GABAB Receptors, Schizophrenia and Sleep Dysfunction. CNS Drugs, 2009, 23, 681-691.	5.9	62
353	Olanzapine dosing above the licensed range is more efficacious than lower doses: fact or fiction?. Expert Review of Neurotherapeutics, 2009, 9, 1045-1058.	2.8	30
354	Weight gain, metabolic parameters, and the impact of race in aggressive inpatients randomized to double-blind clozapine, olanzapine or haloperidol. Schizophrenia Research, 2009, 110, 95-102.	2.0	62
355	Olanzapine Plasma Concentrations After Treatment With 10, 20, and 40 mg/d in Patients With Schizophrenia. Journal of Clinical Psychopharmacology, 2009, 29, 278-283.	1.4	75
356	Medication Nonadherence and Treatment Outcome in Patients With Schizophrenia or Schizoaffective Disorder With Suboptimal Prior Response. Journal of Clinical Psychiatry, 2009, 70, 990-996.	2.2	139
357	How Dosing of Ziprasidone in a State Hospital System Differs From Product Labeling. Journal of Clinical Psychiatry, 2009, 70, 975-982.	2.2	19
358	All Antipsychotics Are Equal, but Some Are More Equal Than Others. Journal of Clinical Psychiatry, 2009, 70, 429-430.	2.2	1
359	Adding Lithium or Anticonvulsants to Antipsychotics for the Treatment of Schizophrenia: Useful Strategy or Exercise in Futility?. Journal of Clinical Psychiatry, 2009, 70, 932-933.	2.2	17
360	The Impact of Ethnicity on Metabolic Outcomes During Treatment With Antipsychotics. Journal of Clinical Psychiatry, 2009, 70, 1608-1609.	2.2	2

#	ARTICLE	IF	CITATIONS
361	Reducing Inpatient Aggression: Does Paying Attention Pay Off?. <i>Psychiatric Quarterly</i> , 2008, 79, 91-95.	2.1	12
362	Compelling or irrelevant? Using number needed to treat can help decide. <i>Acta Psychiatrica Scandinavica</i> , 2008, 117, 412-419.	4.5	140
363	Creating a more productive, clutter-free, paperless office: a primer on scanning, storage and searching of PDF documents on personal computers. <i>International Journal of Clinical Practice</i> , 2008, 62, 363-366.	1.7	9
364	Interpreting and applying the EUFEST results using number needed to treat: antipsychotic effectiveness in first-episode schizophrenia. <i>International Journal of Clinical Practice</i> , 2008, 62, 837-840.	1.7	8
365	Heterogeneity of violence in schizophrenia and implications for long-term treatment. <i>International Journal of Clinical Practice</i> , 2008, 62, 1237-1245.	1.7	140
366	Valproate: do formulations matter?. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2008, 33, 457-457.	1.5	0
367	Loss aversion in schizophrenia. <i>Schizophrenia Research</i> , 2008, 103, 121-128.	2.0	39
368	Olanzapine: review of safety 2008. <i>Expert Opinion on Drug Safety</i> , 2008, 7, 761-769.	2.4	56
369	A new rating scale for negative symptoms: The Motor-Affective-Social Scale. <i>Psychiatry Research</i> , 2008, 160, 346-355.	3.3	20
370	Antipsychotics and hyperprolactinaemia: Clinical recommendations. <i>Journal of Psychopharmacology</i> , 2008, 22, 98-103.	4.0	79
371	Current guidelines and their recommendations for prolactin monitoring in psychosis. <i>Journal of Psychopharmacology</i> , 2008, 22, 90-97.	4.0	41
372	Antipsychotics for the treatment of schizophrenia: likelihood to be helped or harmed, understanding proximal and distal benefits and risks. <i>Expert Review of Neurotherapeutics</i> , 2008, 8, 1079-1091.	2.8	38
373	The emerging physical health challenges of antipsychotic associated hyperprolactinaemia in patients with serious mental illness. <i>Journal of Psychopharmacology</i> , 2008, 22, 3-5.	4.0	9
374	Schizophrenia, Obesity, and Antipsychotic Medications: What Can We Do?. <i>Postgraduate Medicine</i> , 2008, 120, 18-33.	2.0	56
375	Standard and Higher Dose of Olanzapine in Patients With Schizophrenia or Schizoaffective Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2008, 28, 392-400.	1.4	89
376	Public-Academic Partnerships: Integrating State Psychiatric Hospital Treatment and Clinical Research. <i>Psychiatric Services</i> , 2008, 59, 958-960.	2.0	4
377	Datapoints: Did CATIE Influence Antipsychotic Use?. <i>Psychiatric Services</i> , 2008, 59, 476-476.	2.0	5
378	Show Me the Evidence: Now What Do I Do with It?. <i>Southern Medical Journal</i> , 2008, 101, 1197.	0.7	1

#	ARTICLE	IF	CITATIONS
379	Antiepileptics in the Treatment of Schizophrenia. <i>Medical Psychiatry</i> , 2008, , 187-206.	0.2	1
380	Paliperidone: the evidence of its therapeutic value in schizophrenia. <i>Core Evidence</i> , 2008, 2, 261-71.	4.7	12
381	The Treatment of Acute Agitation in Schizophrenia. <i>CNS Spectrums</i> , 2007, 12, 1-16.	1.2	3
382	Show Me the Evidence: Using Number Needed to Treat. <i>Southern Medical Journal</i> , 2007, 100, 881-884.	0.7	28
383	Innovations: Child & Adolescent Psychiatry Training in Developmental Responses to Trauma for Child Service Providers. <i>Psychiatric Services</i> , 2007, 58, 12-14.	2.0	14
384	Pharmacokinetics of Aripiprazole and Concomitant Carbamazepine. <i>Journal of Clinical Psychopharmacology</i> , 2007, 27, 279-283.	1.4	47
385	Lamotrigine as Add-On Therapy in Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2007, 27, 582-589.	1.4	112
386	Risperidone alone versus risperidone plus valproate in the treatment of patients with schizophrenia and hostility. <i>International Clinical Psychopharmacology</i> , 2007, 22, 356-362.	1.7	43
387	Datapoints: The Ups and Downs of Dosing Second-Generation Antipsychotics. <i>Psychiatric Services</i> , 2007, 58, 11-11.	2.0	21
388	The role of adherence to medication in the effectiveness of long-term treatment of schizophrenia. <i>European Psychiatry</i> , 2007, 22, S54-S55.	0.2	2
389	Reviewing CATIE for clinicians:balancing benefit and risk using evidence-based medicine tools. <i>Current Medical Research and Opinion</i> , 2007, 23, 2551-2557.	1.9	15
390	Atypical Antipsychotics, Elderly Patients, and Mortality Risk. <i>Southern Medical Journal</i> , 2007, 100, 964-965.	0.7	8
391	Ziprasidone for Schizophrenia and Bipolar Disorder: A Review of the Clinical Trials. <i>CNS Neuroscience & Therapeutics</i> , 2007, 13, 137-177.	4.0	74
392	Paliperidone: quo vadis?. <i>International Journal of Clinical Practice</i> , 2007, 61, 653-662.	1.7	38
393	Olanzapine: interpreting the label change. <i>International Journal of Clinical Practice</i> , 2007, 61, 1960-1962.	1.7	10
394	The Psychopharmacology of Violence With Emphasis on Schizophrenia, Part 1: Acute Treatment. <i>Journal of Clinical Psychiatry</i> , 2007, 68, 163-164.	2.2	3
395	The Psychopharmacology of Violence With Emphasis on Schizophrenia, Part 2: Long-Term Treatment. <i>Journal of Clinical Psychiatry</i> , 2007, 68, 331-332.	2.2	2
396	Comparison of Intramuscular Ziprasidone, Olanzapine, or Aripiprazole for Agitation. <i>Journal of Clinical Psychiatry</i> , 2007, 68, 1876-1885.	2.2	109

#	ARTICLE	IF	CITATIONS
397	Interpreting and Applying the CATIE Results: With CATIE, context is key, when sorting out Phases 1, 1A, 1B, 2E, and 2T. <i>Psychiatry</i> , 2007, 4, 23-9.	0.3	2
398	Impact factor? Shmimpact factor!: the journal impact factor, modern day literature searching, and the publication process. <i>Psychiatry</i> , 2007, 4, 54-7.	0.3	5
399	Introduction: weighing the evidence: weight management insights for treating major mental illness. <i>Journal of Clinical Psychiatry</i> , 2007, 68 Suppl 12, 4.	2.2	0
400	The effectiveness criterion: balancing efficacy against the risks of weight gain. <i>Journal of Clinical Psychiatry</i> , 2007, 68 Suppl 12, 12-7.	2.2	4
401	Are We Treating Schizophrenia Effectively? Understanding the Primary Outcomes of the CATIE Study. <i>CNS Spectrums</i> , 2006, 11, 1-16.	1.2	6
402	Incidence, Prevalence, and Surveillance for Diabetes in New York State Psychiatric Hospitals, 1997-2004. <i>Psychiatric Services</i> , 2006, 57, 1132-1139.	2.0	20
403	Early Predictors of Substantial Weight Gain in Bipolar Patients Treated with Olanzapine. <i>Journal of Clinical Psychopharmacology</i> , 2006, 26, 316-320.	1.4	72
404	Differential Rates of Treatment Discontinuation in Clinical Trials as a Measure of Treatment Effectiveness for Olanzapine and Comparator Atypical Antipsychotics for Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2006, 26, 632-637.	1.4	26
405	Schizophrenia, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and number needed to treat: how can CATIE inform clinicians?. <i>International Journal of Clinical Practice</i> , 2006, 60, 933-940.	1.7	43
406	Maintenance treatment with olanzapine reduces relapse in people with bipolar I disorder who have responded to acute olanzapine treatment. <i>Evidence-Based Mental Health</i> , 2006, 9, 73-73.	4.5	0
407	Atypical Antipsychotic Agents in the Treatment of Violent Patients With Schizophrenia and Schizoaffective Disorder. <i>Archives of General Psychiatry</i> , 2006, 63, 622.	12.3	294
408	A review of aripiprazole in the treatment of patients with schizophrenia or bipolar I disorder. <i>Neuropsychiatric Disease and Treatment</i> , 2006, 2, 427-443.	2.2	54
409	Efficacy of Ziprasidone Against Hostility in Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2006, 67, 638-642.	2.2	35
410	Best Clinical Practice With Ziprasidone IM: Update After 2 Years of Experience. <i>CNS Spectrums</i> , 2005, 10, 1-15.	1.2	38
411	Dosing of Second-Generation Antipsychotic Medication in a State Hospital System. <i>Journal of Clinical Psychopharmacology</i> , 2005, 25, 388-391.	1.4	32
412	Focus on The clinical ramifications of antipsychotic choice for the risk for developing type 2 diabetes mellitus. <i>International Journal of Neuropsychopharmacology</i> , 2005, 8, 147-151.	2.1	7
413	COMMENTARY: Bipolar disorder is a potentially fatal disease. <i>Postgraduate Medicine</i> , 2005, 117, 9-11.	2.0	4
414	The many faces of bipolar disorder. <i>Postgraduate Medicine</i> , 2005, 117, 15-23.	2.0	12

#	ARTICLE	IF	CITATIONS
415	Latest therapies for bipolar disorder. <i>Postgraduate Medicine</i> , 2005, 117, 25-36.	2.0	23
416	Testing for diabetes. <i>British Journal of Psychiatry</i> , 2005, 186, 78-78.	2.8	4
417	Toward Convergence in the Medication Treatment of Bipolar Disorder and Schizophrenia. <i>Harvard Review of Psychiatry</i> , 2005, 13, 28-42.	2.1	25
418	Metabolic Syndrome and Cardiovascular Disease. <i>Journal of Psychopharmacology</i> , 2005, 19, 84-93.	4.0	78
419	Diabetes and schizophrenia 2005: are we any closer to understanding the link?. <i>Journal of Psychopharmacology</i> , 2005, 19, 56-65.	4.0	89
420	Monotherapy Versus Polypharmacy for Hospitalized Psychiatric Patients. <i>American Journal of Psychiatry</i> , 2005, 162, 631-631.	7.2	15
421	Suggestive association between the C825T polymorphism of the G-protein $\beta 3$ subunit gene (GNB3) and clinical improvement with antipsychotics in schizophrenia. <i>European Neuropsychopharmacology</i> , 2005, 15, 525-531.	0.7	59
422	Do guidelines for severe mental illness promote physical health and well-being?. <i>Journal of Psychopharmacology</i> , 2005, 19, 102-109.	4.0	95
423	Pharmacokinetics of Aripiprazole and Concomitant Lithium and Valproate. <i>Journal of Clinical Pharmacology</i> , 2005, 45, 89-93.	2.0	77
424	The SNAP-25 gene may be associated with clinical response and weight gain in antipsychotic treatment of schizophrenia. <i>Neuroscience Letters</i> , 2005, 379, 81-89.	2.1	93
425	Identification of a naturally occurring 21bp deletion in alpha2c noradrenergic receptor gene and cognitive correlates to antipsychotic treatment. <i>Pharmacological Research</i> , 2005, 51, 381-384.	7.1	8
426	Efficacy of clozapine, olanzapine, risperidone, and haloperidol in schizophrenia and schizoaffective disorder assessed with nurses observation scale for inpatient evaluation. <i>Schizophrenia Research</i> , 2005, 76, 127-129.	2.0	6
427	Metabolic Issues in Patients with Severe Mental Illness. <i>Southern Medical Journal</i> , 2005, 98, 714-719.	0.7	44
428	Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. <i>Journal of Clinical Psychiatry</i> , 2005, 66, 1073-1074.	2.2	14
429	Efficacy of Aripiprazole Against Hostility in Schizophrenia and Schizoaffective Disorder. <i>Journal of Clinical Psychiatry</i> , 2005, 66, 1362-1366.	2.2	34
430	Dosing of Quetiapine in Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2005, 66, 1512-1516.	2.2	50
431	The promise of atypical antipsychotics. <i>Postgraduate Medicine</i> , 2004, 116, 49-63.	2.0	20
432	Relationship Between Antipsychotic Medication Treatment and New Cases of Diabetes Among Psychiatric Inpatients. <i>Psychiatric Services</i> , 2004, 55, 1006-1013.	2.0	101

#	ARTICLE	IF	CITATIONS
433	Olanzapine vs Haloperidol for Treatment of Schizophrenia. JAMA - Journal of the American Medical Association, 2004, 291, 1064.	7.4	1
434	Flexible oral olanzapine dosing in acutely agitated people is immediately effective in reducing symptoms. Evidence-Based Mental Health, 2004, 7, 12-12.	4.5	0
435	Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes: Response to consensus statement. Diabetes Care, 2004, 27, 2087-2088.	8.6	15
436	New Treatments for Agitation. Psychiatric Quarterly, 2004, 75, 197-213.	2.1	30
437	COMT158 polymorphism and hostility. American Journal of Medical Genetics Part A, 2004, 127B, 28-29.	2.4	28
438	Ziprasidone versus haloperidol for the treatment of agitation. Annals of Emergency Medicine, 2004, 44, S22.	0.6	9
439	Re: Treatment Noncompliance with Orally Disintegrating Olanzapine Tablets. Canadian Journal of Psychiatry, 2004, 49, 412-413.	1.9	3
440	A Study of the Safety, Efficacy, and Tolerability of Switching From the Standard Delayed Release Preparation of Divalproex Sodium to the Extended Release Formulation in Patients With Schizophrenia. Journal of Clinical Psychopharmacology, 2004, 24, 255-259.	1.4	16
441	Adjunctive Divalproex and Hostility Among Patients With Schizophrenia Receiving Olanzapine or Risperidone. Psychiatric Services, 2004, 55, 290-294.	2.0	130
442	Overt Aggression and Psychotic Symptoms in Patients With Schizophrenia Treated With Clozapine, Olanzapine, Risperidone, or Haloperidol. Journal of Clinical Psychopharmacology, 2004, 24, 225-228.	1.4	160
443	Antihostility Effects of Adjunctive Divalproex. Psychiatric Services, 2004, 55, 1068-a-1069.	2.0	0
444	Overt Aggression and Psychotic Symptoms in Patients With Schizophrenia Treated With Clozapine, Olanzapine, Risperidone, or Haloperidol. Journal of Clinical Psychopharmacology, 2004, 24, 1-4.	1.4	9
445	Prolactin Levels in Schizophrenia and Schizoaffective Disorder Patients Treated With Clozapine, Olanzapine, Risperidone, or Haloperidol. Journal of Clinical Psychiatry, 2004, 65, 57-61.	2.2	151
446	Effects of Atypical Antipsychotics on the Syndromal Profile in Treatment-Resistant Schizophrenia. Journal of Clinical Psychiatry, 2004, 65, 551-556.	2.2	59
447	Changes in Glucose and Cholesterol Levels in Patients With Schizophrenia Treated With Typical or Atypical Antipsychotics. American Journal of Psychiatry, 2003, 160, 290-296.	7.2	450
448	Efficacy of the Branched-Chain Amino Acids in the Treatment of Tardive Dyskinesia in Men. American Journal of Psychiatry, 2003, 160, 1117-1124.	7.2	73
449	Atypical antipsychotics for acute agitation. Postgraduate Medicine, 2002, 112, 85-96.	2.0	35
450	Clozapine, Olanzapine, Risperidone, and Haloperidol in the Treatment of Patients With Chronic Schizophrenia and Schizoaffective Disorder. American Journal of Psychiatry, 2002, 159, 255-262.	7.2	377

#	ARTICLE	IF	CITATIONS
451	Neurocognitive Effects of Clozapine, Olanzapine, Risperidone, and Haloperidol in Patients With Chronic Schizophrenia or Schizoaffective Disorder. <i>American Journal of Psychiatry</i> , 2002, 159, 1018-1028.	7.2	493
452	Managing Treatment-Resistant Schizophrenia: Evidence from Randomized Clinical Trials. <i>Journal of Psychiatric Practice</i> , 2002, 8, 205-215.	0.7	30
453	Antipsychotic-Induced Weight Gain and Therapeutic Response: A Differential Association. <i>Journal of Clinical Psychopharmacology</i> , 2002, 22, 244-251.	1.4	149
454	Neurocognitive correlates of the COMT Val158Met polymorphism in chronic schizophrenia. <i>Biological Psychiatry</i> , 2002, 52, 701-707.	1.3	304
455	Optimal Dosing of Atypical Antipsychotics in Adults: A Review of the Current Evidence. <i>Harvard Review of Psychiatry</i> , 2002, 10, 280-291.	2.1	78
456	Atypical antipsychotics: revolutionary or incremental advance?. <i>Expert Review of Neurotherapeutics</i> , 2002, 2, 69-88.	2.8	22
457	Datapoints: Use of Mood Stabilizers Among Patients With Schizophrenia, 1994-2001. <i>Psychiatric Services</i> , 2002, 53, 1212-1212.	2.0	45
458	Optimizing dosing in atypical neuroleptic monotherapy. <i>Dialogues in Clinical Neuroscience</i> , 2002, 4, 438-443.	3.7	1
459	Olanzapine in Refractory Schizophrenia After Failure of Typical or Atypical Antipsychotic Treatment. <i>Journal of Clinical Psychiatry</i> , 2002, 63, 931-935.	2.2	54
460	Dr. Bilder and Colleagues Reply. <i>American Journal of Psychiatry</i> , 2002, 159, 2118-a-2119.	7.2	0
461	Optimal Dosing of Atypical Antipsychotics in Adults: A Review of the Current Evidence. <i>Harvard Review of Psychiatry</i> , 2002, 10, 280-291.	2.1	4
462	Olanzapine for Schizophrenia Refractory to Typical and Atypical Antipsychotics: An Open-Label, Prospective Trial. <i>Journal of Clinical Psychopharmacology</i> , 2001, 21, 448-453.	1.4	31
463	Effects of Clozapine, Olanzapine, Risperidone, and Haloperidol on Hostility Among Patients With Schizophrenia. <i>Psychiatric Services</i> , 2001, 52, 1510-1514.	2.0	177
464	Antiaggressive Effect of Quetiapine in a Patient With Schizoaffective Disorder. <i>Journal of Clinical Psychiatry</i> , 2001, 62, 901.	2.2	11
465	Changes in Use of Valproate and Other Mood Stabilizers for Patients With Schizophrenia From 1994 to 1998. <i>Psychiatric Services</i> , 2000, 51, 634-638.	2.0	101
466	FC09.05 Clozapine, olanzapine, risperidone, and haloperidol in refractory schizophrenia. <i>European Psychiatry</i> , 2000, 15, 284s-284s.	0.2	5
467	Pharmacological Interventions for Preventing Violence Among the Mentally Ill with Co-Occurring Personality Disorders. , 2000, , 193-209.		2
468	Management of Violence in Schizophrenia. <i>Psychiatric Annals</i> , 2000, 30, 41-52.	0.1	18

#	ARTICLE	IF	CITATIONS
469	VIOLENT PATIENTS IN THE EMERGENCY SETTING. <i>Psychiatric Clinics of North America</i> , 1999, 22, 789-801.	1.3	49
470	Atypical antipsychotics in the treatment of the persistently aggressive psychotic patient: methodological concerns. <i>Schizophrenia Research</i> , 1999, 35, S23-S33.	2.0	52
471	Violence in Schizophrenia. <i>Journal of Psychiatric Practice</i> , 1999, 5, 326-335.	0.7	4
472	Schizophrenia: violence and comorbidity. <i>Current Opinion in Psychiatry</i> , 1999, 12, 47-51.	6.3	14
473	Utilization of valproate: extent of inpatient use in the New York State Office of Mental Health. <i>Psychiatric Quarterly</i> , 1998, 69, 283-300.	2.1	42
474	Practice protocols, parameters, pathways, and guidelines: a review. <i>Administration and Policy in Mental Health and Mental Health Services Research</i> , 1998, 25, 257-269.	2.1	7
475	Safety of Accutane with possible depression. <i>Postgraduate Medicine</i> , 1998, 104, 38-38.	2.0	12
476	New antipsychotic medications. <i>Postgraduate Medicine</i> , 1997, 101, 207-214.	2.0	15
477	Layoffs, reductions-in-force, downsizing, rightsizing: The case of a state psychiatric hospital. <i>Administration and Policy in Mental Health and Mental Health Services Research</i> , 1997, 24, 523-533.	2.1	0
478	Psychopharmacology of Violence: Part I: Assessment and Acute Treatment. <i>Psychiatric Annals</i> , 1997, 27, 691-695.	0.1	14
479	Psychopharmacology of Violence: Part II: Beyond the Acute Episode. <i>Psychiatric Annals</i> , 1997, 27, 696-703.	0.1	18
480	Adjunctive Nadolol in the Treatment of Acutely Aggressive Schizophrenic Patients. <i>Journal of Clinical Psychiatry</i> , 1996, 57, 455-459.	2.2	30
481	Utilization of depot neuroleptic medication in psychiatric inpatients. <i>Psychopharmacology Bulletin</i> , 1996, 32, 321-6.	0.0	27
482	Transient Elevations in Pancreatic Enzymes in Response to a Cholinesterase Inhibitor. <i>Clinical Neuropharmacology</i> , 1995, 18, 464-465.	0.7	0
483	Depression screening. <i>Psychiatric Services</i> , 1995, 46, 186-187.	2.0	1
484	Clinical and administrative consequences of a reduced census on a Psychiatric Intensive Care Unit. <i>Psychiatric Quarterly</i> , 1995, 66, 209-217.	2.1	4
485	Personal computers in risk management and incident reporting. <i>Administration and Policy in Mental Health and Mental Health Services Research</i> , 1995, 22, 511-519.	2.1	1
486	Use of Lithium, Carbamazepine, and Valproic Acid in a State-Operated Psychiatric Hospital. <i>Journal of Pharmacy Technology</i> , 1995, 11, 55-59.	1.0	25

#	ARTICLE	IF	CITATIONS
487	Management of depression. Postgraduate Medicine, 1994, 95, 137-145.	2.0	6
488	Length of Stay and Recidivism on a Psychiatric Intensive Care Unit. Psychiatric Services, 1994, 45, 74-76.	2.0	13
489	Management of depression. Current options for this highly treatable disorder. Postgraduate Medicine, 1994, 95, 137-42, 45.	2.0	1
490	The dangerous agitated patient. Postgraduate Medicine, 1990, 87, 231-236.	2.0	13
491	A double-blind, placebo-controlled study of adjunctive nadolol in the management of violent psychiatric patients. Psychopharmacology Bulletin, 1990, 26, 367-71.	0.0	23
492	Differential diagnosis of psychosis. Postgraduate Medicine, 1989, 85, 273-280.	2.0	10
493	Dissemination of clinical trial information: multiple audiences, multiple formats. , 0, , 169-176.		0
494	Psychopharmacology of Violence. , 0, , 645-653.		0
495	AXS-05: an investigational treatment for Alzheimer's disease-associated agitation. Expert Opinion on Investigational Drugs, 0, , 1-8.	4.1	2